Novel therapeutic approaches to Guillain-Barre syndrome

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2307-2318

  Pritchard, J ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; Guillain Barre syndrome; Immunology; Peripheral nerve

Indexed keywords

AUTOANTIGEN; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D; CORTICOSTEROID; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GLYCOSPHINGOLIPID; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN; MYELIN BASIC PROTEIN; MYELIN PROTEIN; SIALIC ACID DERIVATIVE; STEROID; TRANSFORMING GROWTH FACTOR BETA; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CONVALESCENCE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ACTIVITY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; NEURITIS; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; RAT; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0033780601     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2307     Document Type: Review

References (108)

1. Note sur la paralysie ascendante aigue
2. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux
3. Pathogenesis of Guillain-Barre syndrome
4. Electrophysiological classification of Guillain-Barre syndrome: Clinical associations and outcome
5. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China
6. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome
7. Paralytic syndromes associated with non-inflammatory cytoplasmic or nuclear neuropathy
8. Acute idiopathic axonal neuropathy (AIAN): A clinical and electrophysiological observation
9. The inflammatory lesion in idiopathic polyneuritis
10. Acute idiopathic polyneuritis. An electronmicroscopic study
11. Pathology of the Guillain-Barre syndrome
12. Quantitative analysis of endoneurial T cells in human sural nerve biopsies
13. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy
14. A clinicopathological study of Guillain-Barre syndrome: Nine cases and literature review
15. Immune mediated attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy
16. A prospective study of acute idiopathic neuropathy. II: Antecedent events
17. The spectrum of antecedent infections in Guillain-Barre syndrome: A case control study
18. Immunologic studies of rabies vaccination-induced GBS
19. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-77: Results of a two-state study
20. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome
21. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside
22. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release
23. Serum anti-GQ1b antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: Clinical and immunohistochemical studies
24. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome
25. Localization of GM1 and Gal(β1-3)GalNAc antigenic determinants in peripheral nerve
26. Serum antibodies to GM1, GD1b, peripheral nerve myelin and campylobacter jejuni in patients with Guillain-Barre syndrome and controls: Correlation and prognosis
27. Antibody responses to P0 and P2 myelin proteins in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculopathy
28. Anti-PMP22 antibodies in patients with inflammatory neuropathy
29. Guillain-Barre syndrome in mother and newborn child
30. Neonatal Guillain-Barre syndrome. Blocking antibodies transmitted from mother to child
31. Expression of integrins in experimental autoimmune neuritis and Guillain-Barre syndrome
32. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller-Fisher syndrome
33. IgG anti-GM1 antibodies from patients with acute motor neuropathy are predominantly of the IgG1 and IgG3 subclasses
34. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculneuropathy: Comparison with other neurological disease of presumed immunopathogenesis
35. T cell activation in Guillain-Barre syndrome and in MS: Elevated levels of soluble IL-2 receptors
36. Clinical correlation with serum soluble interleukin-2 receptor levels in Guillain-Barre syndrome
37. T lymphocyte activation antigens in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy
38. T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain-Barre syndrome
39. A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barre syndrome
40. T helper Type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barre syndrome
41. Transforming growth factor β expression in reactive spinal cord microglia and meningeal inflammatory cells during experimental allergic neuritis
42. T cell responses to myelin proteins in Guillain-Barre syndrome
43. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma
44. Allergic neuritis: Experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants
45. Mechanism of demyelination in experimental allergic neuritis. Electron microscopic studies
46. Identification of the neuritogen for experimental allergic neuritis
47. P0 myelin protein produces experimental allergic neuritis in Lewis rats
48. Induction of experimental neuritis with peripheral myelin protein 22
49. A permanent rat T cell line that mediates experimental allergic neuritis in the rat in vivo
50. Morphological study on EAN mediated by T-cell line specific for bovine P2 protein in Lewis rats
51. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: Induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines
52. Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis
53. Human immunoglobulin ameliorates rat experimental autoimmune neuritis
54. Failure of intravenous immunoglobulin therapy in experimental autoimmune neuritis of the Lewis rat
55. Insights into the Campylobacter jejuni-induced Guillain-Barre syndrome from the Lewis rat model of experimental allergic neuritis
56. Plasmapharesis and acute Guillain-Barre syndrome
57. Plasma exchange in Guillain-Barre syndrome: One year follow up
58. Appropriate number of plasma exchanges in Guillain-Barre syndrome
59. A randomised trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome
60. Treatment of immunemediated inflammatory neuropathies
61. Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barre syndrome
62. Cerebral infarction complicating intravenous immunoglobulin therapy in Miller Fisher syndrome
63. Controlled trial of prednisolone in acute polyneuropathy
64. The use of steroids in the treatment of idiopathic polyneuritis
65. Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study
66. Corticosteroids for treating Guillain-Barre syndrome
67. Vaccines against Campylobacter jejuni
68. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni
69. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects
70. A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats
71. Tolerance and autoimmunity
72. Antigen-specific immunosuppression: Nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats
73. Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis
74. Antigen-based immunotherapy for autoimmune disease: From animal models to humans
75. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat
76. Suppression of experimental autoimmune neuritis by antibodies to the intercellular adhesion molecule-1
77. Inhibition of experimental autoimmune neuritis by antibody to the leukocyte function associated antigen-1
78. Attenuation of experimental autoimmune neuritis in the Lewis rat by treatment with antibody to L-selectin
79. T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies
80. Treatment of Guillain-Barre syndrome with anti-T cell monoclonal antibodies
81. Finally, CTLA4-Ig graduates to the clinic
82. A randomised prospective trial of anti-Tac monoclonal antibody in human renal transplantation
83. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre syndrome
84. The expression of cytokine mRNA in the cauda equina of Lewis rats with experimental allergic neuritis
85. Tumor necrosis factor-α in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system
86. Suppression of chronic experimental autoimmune neuritis by nasally administered recombinant rat interleukin-6
87. Dynamics of production of MIP-1α, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses in experimental autoimmune neuritis in Lewis rats
88. Biological insights from clinical trials with anti-TNF therapy
89. Inhibitors of tumor necrosis factor-α: Promising agents for the treatment of multiple sclerosis?
90. Immune reactive C3d on the surface myelin sheaths in neuropathy
91. Complement depletion suppresses Lewis rat experimental allergic neuritis
92. Soluble complement receptor Type 1 inhibits experimental autoimmune neuritis in Lewis rats
93. Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis
94. Matrix metalloproteinase expression during experimental autoimmune neuritis
95. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor α processing attenuates experimental autoimmune neuritis
96. Demyelination: The role of reactive oxygen and nitrogen species
97. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis
98. Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase
99. The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis
100. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
101. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide
102. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses
103. Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats
104. Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats
105. Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
106. Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
107. Interferon-β 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
108. Treatment of Guillain-Barre syndrome with interferon-β